- Report
- September 2024
- 100 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 140 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- January 2024
- 200 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- March 2025
- 92 Pages
China
From €1638EUR$1,800USD£1,404GBP
- Report
- April 2024
- 160 Pages
Global
From €4522EUR$4,969USD£3,877GBP
- Report
- March 2025
- 251 Pages
China
From €3640EUR$4,000USD£3,121GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Ziprasidone is a medication used to treat mental disorders such as schizophrenia, bipolar disorder, and depression. It is a second-generation antipsychotic drug, which means it is more effective and has fewer side effects than first-generation antipsychotics. Ziprasidone works by blocking certain receptors in the brain, which helps to reduce symptoms of mental illness. It is available in both oral and injectable forms.
Ziprasidone is a popular choice for treating mental disorders due to its effectiveness and low risk of side effects. It is also relatively affordable, making it a viable option for many patients. Additionally, it has been approved for use in children and adolescents, making it a viable option for treating mental illness in this population.
The Ziprasidone market is highly competitive, with many companies offering the drug. Some of the major players in the market include Pfizer, Sun Pharmaceuticals, Mylan, and Teva Pharmaceuticals. Show Less Read more